ABSTRACT
Background Long COVID has been associated with reduced exercise capacity, but whether SARS-CoV-2 infection or Long COVID is associated with reduced exercise capacity among people with HIV (PWH) has not been reported. We hypothesized that PWH with cardiopulmonary post-acute symptoms of COVID-19 (PASC) would have reduced exercise capacity due to chronotropic incompetence.
Methods We conducted cross-sectional cardiopulmonary exercise testing within a COVID recovery cohort that included PWH. We evaluated associations of HIV, prior SARS-CoV-2 infection, and cardiopulmonary PASC with exercise capacity (peak oxygen consumption, VO2) and adjusted heart rate reserve (AHRR, chronotropic measure) with adjustment for age, sex, and body mass index.
Results We included 83 participants (median age 54, 35% female). All 37 PWH were virally suppressed; 23 (62%) had prior SARS-CoV-2 infection, and 11 (30%) had PASC. Peak VO2 was reduced among PWH (80% predicted vs 99%; p=0.005), a difference of 5.5 ml/kg/min (95%CI 2.7-8.2, p<0.001). Chronotropic incompetence more prevalent among PWH (38% vs 11%; p=0.002), and AHRR was reduced among PWH (60% vs 83%, p<0.0001). Among PWH, exercise capacity did not vary by SARS-CoV-2 coinfection, but chronotropic incompetence was more common among PWH with PASC: 3/14 (21%) without SARS-CoV-2, 4/12 (25%) with SARS-CoV-2 without PASC, and 7/11 (64%) with PASC (p=0.04 PASC vs no PASC).
Conclusions Exercise capacity and chronotropy are lower among PWH compared to SARS-CoV-2 infected individuals without HIV. Among PWH, SARS-CoV-2 infection and PASC were not strongly associated with reduced exercise capacity. Chronotropic incompetence may be a mechanism limiting exercise capacity among PWH.
Competing Interest Statement
PYH has received modest honoraria from Gilead and Merck and research grant from Novartis unrelated to the submitted work. MJP has served as a consultant for AstraZeneca and Gilead Sciences, outside the submitted work. All other authors have declared that no conflict of interest exists.
Funding Statement
This study was funded by philanthropic gifts from Charles W. Swanson, a grant from the NIH/NLBI (K12 HL143961), internal funds from the Division of Cardiology at Zuckerberg San Francisco General, and by a grant from the National Institutes of Health/NIAID (R01 AI158013). This work was supported by a UCSF-Gladstone CFAR Mentored Scientist Award via NIH grant to the UCSF-Gladstone Center for AIDS Research (P30AI027763). TJH is supported by NIH/NIAID 3R01A1141003-03S1. This publication was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through UCSF-CTSI Grant Number UL1TR001872. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The University of California San Francisco Institutional Review Board granted ethical approval for this study (IRB 20-33000), and all participants provided written informed consent prior to participation.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Presented at the Conference on Retroviruses and Opportunistic Infections in Seattle, WA February 2023.
Disclosures: PYH has received modest honoraria from Gilead and Merck and research grant from Novartis unrelated to the submitted work. MJP has served as a consultant for AstraZeneca and Gilead Sciences, outside the submitted work. All other authors have declared that no conflict of interest exists.
Funding: This study was funded by philanthropic gifts from Charles W. Swanson, a grant from the NIH/NLBI (K12 HL143961), internal funds from the Division of Cardiology at Zuckerberg San Francisco General, and by a grant from the National Institutes of Health/NIAID (R01 AI158013). This work was supported by a UCSF-Gladstone CFAR Mentored Scientist Award via NIH grant to the UCSF-Gladstone Center for AIDS Research (P30AI027763). TJH is supported by NIH/NIAID 3R01A1141003-03S1. This publication was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through UCSF-CTSI Grant Number UL1TR001872. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
